American journal of translational research最新文献

{"title":"AGTR1 inhibits pyroptosis and inflammatory cytokine secretion in rheumatoid arthritis fibroblast-like synoviocytes through the TGF-β pathway.","authors":"Jian Wang, Zongbiao Bai","doi":"10.62347/HTCE3264","DOIUrl":"10.62347/HTCE3264","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease. The hyperactivation of fibroblast-like synoviocytes (FLS) is a major contributor to synovial hyperplasia and cartilage destruction, and FLS pyroptosis plays a pivotal role in RA pathogenesis. This study aimed to investigate the mechanisms by which AGTR1 regulates FLS pyroptosis and inflammatory cytokine secretion in RA to identify potential therapeutic targets for RA.</p><p><strong>Methods: </strong>Bioinformatic analysis assessed AGTR1 expression levels using the GSE21959 and GSE55235 datasets. qRT-PCR and western blot (WB) measured AGTR1 mRNA and protein levels in cell lines. Nigericin (a pyroptosis inducer), the TGF-β receptor I inhibitor SB505124, and the TGF-β neutralizing antibody 1D11 were administered to AGTR1-overexpressing RA-FLS, followed by western blot analysis of pyroptosis-related proteins. Flow cytometry, LDH assays, and propidium iodide staining evaluated pyroptosis levels. ELISA measured inflammatory cytokine secretion. WB confirmed TGF-β pathway activation.</p><p><strong>Results: </strong>AGTR1 was downregulated in RA-FLS. AGTR1 overexpression suppressed ASC, NLRP3, cleaved caspase-1, and GSDMD-N expression, thereby alleviating pyroptosis in RA-FLS (<i>P</i> < 0.05). AGTR1 overexpression inhibited secretion of inflammatory cytokines and reduced lactate dehydrogenase release (<i>P</i> < 0.05). We demonstrated that AGTR1-mediated repression of pyroptosis and inflammatory cytokine secretion in RA-FLS was dependent on the TGF-β signaling pathway.</p><p><strong>Conclusion: </strong>AGTR1 inhibits pyroptosis and attenuates inflammatory cytokine secretion in RA-FLS through TGF-β. These findings suggest that AGTR1 induction or TGF-β pathway activation may ameliorate RA pathology.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7463-7475"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined PDGF and ANGPTL4 in diabetic foot: diagnostic value and exploratory early changes after plantar arch angioplasty plus alprostadil.","authors":"Ping Sui, Ganchun Wu, Juan Wu, Shouguang Sui","doi":"10.62347/HMIF6269","DOIUrl":"10.62347/HMIF6269","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the diagnostic value of combined platelet-derived growth factor (PDGF) and angiopoietin-like protein 4 (ANGPTL4) for distinguishing diabetic foot (DF) from diabetes mellitus (DM) without DF, and to explore their early changes following treatment initiation and their associations with 3-month ulcer healing.</p><p><strong>Methods: </strong>Clinical data were retrospectively collected from January 2024 to May 2025. Before propensity score matching (PSM), 153 patients with DF and 116 non-DF DM patients met the eligibility criteria; after 1:1 PSM, 97 patients were retained in each group. Serum PDGF and ANGPTL4 were measured at baseline in both groups, with additional measurements taken on day 5 after the initiation of plantar arch angioplasty (PAA) and alprostadil in the DF group. The primary analysis evaluated the diagnostic performance of the baseline biomarkers using receiver operating characteristic (ROC) curves, while secondary exploratory analyses assessed their day-5 changes and associations with 3-month ulcer healing.</p><p><strong>Results: </strong>At baseline, PDGF was 26.23% lower and ANGPTL4 was 32.22% higher in the DF group than in the matched DM group (both P<0.05). The combined baseline model yielded an area under the curve (AUC) of 0.805, surpassing the performance of either biomarker alone. Both biomarkers were also associated with ulcer size, Wagner grade, fasting plasma glucose, and hemoglobin A1c. On day 5 after PAA and alprostadil initiation, PDGF significantly increased and ANGPTL4 significantly decreased relative to baseline (both P<0.05). At 3 months, 66 of 97 patients achieved complete ulcer healing; the combined day-5 model discriminated healing status with an AUC of 0.764, a sensitivity of 59.09%, and a specificity of 87.10%.</p><p><strong>Conclusion: </strong>The combination of baseline PDGF and ANGPTL4 improved DF discrimination compared with either biomarker alone. Their day-5 changes and associations with 3-month ulcer healing were exploratory and should not be interpreted as evidence of treatment efficacy or validated prognostic utility.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7476-7486"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wogonoside alleviates ulcerative colitis-induced senescence by activating AMPK in <i>in vivo</i> and <i>in vitro</i> models.","authors":"Ning Luo, Yixia Wei, Zhaohui Tan, Jiaqi Fang, Xiaolu Chen","doi":"10.62347/NLXM4425","DOIUrl":"10.62347/NLXM4425","url":null,"abstract":"<p><p>Ulcerative colitis (UC), a chronic inflammatory bowel disease, causes extensive damage, primarily affecting the colonic mucosa, where persistent inflammation leads to conditions such as mucosal congestion. Recent studies suggest a reciprocal interaction between intestinal cell senescence and inflammation; however, the connection between senescence and UC remains underexplored. Wogonoside, a key active component of Huangqin Decoction, has unclear effects on intestinal cell and tissue senescence in the context of UC.</p><p><strong>Methods: </strong>Dextran Sodium Sulfate (DSS)-induced UC cell and animal models were employed to investigate the potential therapeutic effects of Wogonoside on intestinal epithelial cell senescence and its underlying mechanisms.</p><p><strong>Results: </strong>DSS treatment induced senescence in intestinal cells. Wogonoside alleviated senescence, as indicated by reduced levels of senescence markers (SA-β-gal, p16, p21, p53) and decreased epithelial damage, evidenced by increased occludin and ZO-1 expression. Mechanistic studies revealed that Wogonoside activates the AMPK signaling pathway, attenuating ROS production and thereby preventing intestinal cell senescence and injury. <i>In vivo</i>, Wogonoside similarly reduced DSS-induced senescence, as demonstrated by senescence marker analysis.</p><p><strong>Conclusion: </strong>This study demonstrates that Wogonoside mitigates UC-induced intestinal cell senescence and epithelial barrier disruption by activating the AMPK pathway and reducing ROS production, offering protective effects in both cellular and animal models. These findings suggest that Wogonoside may be a promising therapeutic strategy for the treatment of UC.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7053-7074"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of treatment for acute hexavalent chromium poisoning in human renal proximal tubular epithelial cells with 2,3-dimercapto-1-propanesulfonic acid (DMPS).","authors":"I-Jeng Yeh, Hsin-Liang Liu, Chin-Shen Lin, Po-Min Chang, Ling-Yu Wu, Yi-Chun Tsai, Ya-Ling Hsu, Meng-Chi Yen","doi":"10.62347/TKBM7718","DOIUrl":"10.62347/TKBM7718","url":null,"abstract":"<p><strong>Objectives: </strong>Chelating agents have been utilized in clinical settings to counteract various heavy metal poisonings, although there are currently no established medical guidelines supporting the use of the chelating agent 2,3-dimercapto-1-propanesulfonic acid (DMPS) for treating acute hexavalent chromium (Cr(VI)) poisoning.</p><p><strong>Methods: </strong>Since systemic acute Cr(VI) poisoning has been associated with nephrotoxicity in clinical cases, this study utilized the immortalized human renal epithelial cell line HK-2 and primary proximal tubular epithelial cells (RPTEC) as <i>in vitro</i> models to explore potential treatments.</p><p><strong>Results: </strong>In the HK-2 cell model, cell viability dropped below 50% after exposure to 10 μmol/L Cr(VI) for 32 hours. Both simultaneous administration of 10 μmol/L Cr(VI) with 100 or 300 μg/mL DMPS and delayed treatment with DMPS after two hours effectively reduced Cr(VI)-induced cell death. Furthermore, in the RPTEC cell model, DMPS treatments ranging from 300 to 1000 μg/mL demonstrated significant protective effects on cell viability against Cr(VI) toxicity, mirroring the results observed in the HK-2 model. In contrast, meso-2,3-dimercaptosuccinic acid, another chelating agent, did not exhibit protective effects on HK-2 cells.</p><p><strong>Conclusions: </strong>These findings support DMPS as a promising antidote for acute Cr(VI) poisoning in kidney cells and provide valuable insights for potential clinical applications.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7177-7188"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of liposomal bupivacaine versus ropivacaine for fascia iliaca compartment block on postoperative pain and delirium in elderly patients undergoing hip arthroplasty.","authors":"Liping Cao, Jianwei Zhong, Yan Li, Jian Zhong","doi":"10.62347/LLXS3137","DOIUrl":"10.62347/LLXS3137","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effects of fascia iliaca compartment block (FICB) with liposomal bupivacaine versus ropivacaine on postoperative pain and delirium in elderly patients undergoing total hip arthroplasty (THA).</p><p><strong>Methods: </strong>Eighty-six elderly patients who underwent THA were retrospectively enrolled. They were divided into a liposomal bupivacaine group (LB group, n=43) and a ropivacaine group (R group, n=43) based on the medication administered. Perioperative hemodynamic parameters, inflammatory markers, postoperative pain intensity, incidence of delirium, analgesic use, postoperative recovery outcomes, and complication rates were compared between the groups.</p><p><strong>Results: </strong>The LB group had significantly lower Numerical Rating Scale scores than the R group both at rest and on movement at 12, 24, 48, and 72 hours postoperatively (P<0.05). The LB group had significantly lower inflammatory marker levels than the R group at 24 and 48 hours postoperatively. The LB group had a significantly lower incidence of postoperative delirium (POD) than the R group (4.65% vs. 18.60%, P<0.05). The LB group had fewer patient-controlled intravenous analgesia (PCIA) attempts, longer time to first PCIA, and lower sufentanil consumption postoperatively (P<0.05). The LB group had significantly shorter time to first ambulation and length of hospital stay compared with the LB group (P<0.05).</p><p><strong>Conclusion: </strong>FICB with liposomal bupivacaine may be associated with prolonged analgesia, a lower incidence of POD, faster recovery, and fewer complications in elderly patients undergoing THA.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6640-6650"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Explainable machine learning-based multiphase contrast-enhanced CT radiomics for noninvasively predicting GPC3 expression in hepatocellular carcinoma: a bicentric study.","authors":"Wangwang Lin, Changkai Chen, Xue Wang","doi":"10.62347/IVMH4590","DOIUrl":"10.62347/IVMH4590","url":null,"abstract":"<p><strong>Objectives: </strong>Accurate pre-operative prediction of Glypican-3 (GPC3) profiles in hepatocellular carcinoma (HCC) is essential for selecting candidates for targeted therapy and individualized treatment. This study aimed to develop and externally validate an explainable machine learning model for noninvasively prediction of GPC3 expression in HCC.</p><p><strong>Methods: </strong>A total of 301 HCC patients were retrospectively enrolled from two centers (Center 1: 241; Center 2: 60) between January 2016 and September 2024. Radiomics features were extracted from arterial (AP), portal venous (PVP), and delayed phase (DP) images. Robust features were selected via a sequential pipeline including interobserver agreement screening (intraclass correlation coefficient [ICC] > 0.8), Spearman correlation analysis (Ρ > 0.85), and recursive feature elimination (RFE). Single-phase (AP, PVP, DP), combined-phase (APD) radiomics, clinical, and clinical-radiomics models were constructed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), and SHAP analysis was applied for model interpretability.</p><p><strong>Results: </strong>The combined clinical-radiomics model outperformed the clinical model, achieving an AUC of 0.886 in the training cohort, 0.880 during internal validation cohort, and 0.839 during external validation cohort (P < 0.05). The APD radiomics model showed performance non-inferior to that of the combined model (P > 0.05) and outperformed all single-phase models. AFP > 7 ng/mL (OR=3.257) and intratumoral necrosis (OR=2.947), as confirmed by multivariate logistic regression, were independent predictors for GPC3 positivity. SHAP analysis further identified radiomics score as the most influential predictor (mean |SHAP|=1.84).</p><p><strong>Conclusion: </strong>The multiphase CECT radiomics-based combined model demonstrates good cross-center generalizability and enables accurate noninvasive prediction of GPC3 expression status in HCC. This model may provide a reliable imaging-based tool for screening candidate patients for GPC3-targeted therapies.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7259-7270"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FCGBP promotes malignant phenotypes of glioblastoma cells via activation of the TGF-β1 signaling pathway.","authors":"Jinning Zhang, Lingtong You, Junhuai Wei, Xinyao Chen, Huangqiang Yang, Jiaxin Huang, Huihang Wang, Zhixian Jiang","doi":"10.62347/NVYV1514","DOIUrl":"10.62347/NVYV1514","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the expression level of IgG Fc-binding protein (FCGBP) in glioma cells, elucidate its role in malignant tumor phenotypes, and explore its relationship with the transforming growth factor-β (TGF-β) signaling pathway.</p><p><strong>Methods: </strong>The expression of FCGBP was compared between primary human astrocytes (HA) and glioma cell lines (U87, U251, LN229, and T98G). FCGBP was then silenced in U87 cells. Cell proliferation, migration, and invasion were assessed using Cell Counting Kit-8, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, colony formation, wound healing, and Matrigel-coated Transwell assays. Apoptosis and cell-cycle distribution in U87 cells were analyzed by flow cytometry. Co-immunoprecipitation (Co-IP) was performed to validate the endogenous association between FCGBP and TGF-β1-containing protein complexes. Rescue experiments were conducted using recombinant TGF-β1 protein. Additionally, the in vitro findings were further validated in nude mouse xenograft models.</p><p><strong>Results: </strong>FCGBP was highly expressed in various glioma cell lines, and its knockdown reduced TGF-β levels in the culture supernatant. Knockdown of FCGBP in U87 cells significantly suppressed malignant behaviors, including proliferation, migration, and invasion, while inducing apoptosis and cell-cycle arrest. Co-IP assays suggested an endogenous association between FCGBP and TGF-β1-containing protein complexes, and treatment with recombinant TGF-β1 effectively reversed the inhibitory effects of FCGBP knockdown. <i>In vivo</i> experiments confirmed that silencing FCGBP markedly inhibited tumor growth in nude mice and significantly reduced systemic inflammation and TGF-β levels.</p><p><strong>Conclusion: </strong>FCGBP promotes malignant phenotypes in glioma cells (U87) and accelerates tumor growth <i>in vivo</i>, potentially through activation of the TGF-β/Smad signaling pathway.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6550-6567"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role and mechanism of CHST6-mediated lactation modification in lenvatinib resistance in hepatocellular carcinoma cells.","authors":"Dongdong Wang, Hongqiang Gao, Li Li","doi":"10.62347/JQSF1666","DOIUrl":"10.62347/JQSF1666","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death. Approximately 70% of HCC patients present with advanced-stage disease at the time of diagnosis. Lenvatinib is a standard first-line treatment for HCC; however, the development of drug resistance substantially limits its therapeutic efficacy.</p><p><strong>Methods: </strong>Genes associated with lactylation and lenvatinib resistance were identified through bioinformatic analyses. Differentially expressed genes (DEGs) were screened using data from the TCGA-LIHC cohort, the GSE186191 dataset, and a lactylation-related gene datasets. Receiver operating characteristic (ROC) curve analysis, Cox regression analysis, survival analysis, and prognostic evaluation were performed to analyze the association between identified genes and treatment outcomes. After constructing the lenvatinib-resistant MHCC97 cell line (MHCC97-LR) was established, and the effects of CHST6 knockdown on cell viability, apoptosis, cell cycle, lactate content, and the expression of lactylation-related genes were analyzed.</p><p><strong>Results: </strong>A total of 15 overlapping DEGs related to both lactylation and lenvatinib resistance were identified. These genes were involved in multiple metabolic pathways, including lipid and glucose metabolism. CHST6, SPAG4, and PFKFB4 exhibited excellent diagnostic performance for HCC, and their lower expression levels were correlated with favorable prognosis. Cox regression analysis identified CHST6 as the only gene significantly associated with HCC prognosis, demonstrating predictive value for 1-5-year survival in HCC patients. Strikingly, enhanced lactylation was associated with elevated CHST6 expression and greater cell viability in MHCC97-LR cells. Furthermore, CHST6 knockdown reduced the lactate production and the expression of lactylation-associated proteins (Pan-Kla, H3K18la, and H3K56la) in MHCC97-LR cells, along with increased apoptosis and G1-phase cell-cycle arrest in MHCC97-LR cells.</p><p><strong>Conclusion: </strong>CHST6 knockdown reduces intracellular lactate contents and lactylation in MHCC97-LR cells, thereby attenuating lenvatinib resistance and enhancing the antitumor efficacy of lenvatinib in HCC.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"6612-6626"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overweight and obesity are associated with poorer treatment response and impaired pulmonary function in children with bronchial asthma: a retrospective study.","authors":"Bingjie Wang, Juan Huang, Xiangteng Liu, Jiabiao Lin, Qiao Liang, Bo Wang, Guilan Wang","doi":"10.62347/FEMJ5128","DOIUrl":"10.62347/FEMJ5128","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of body mass index (BMI) on standardized treatment efficacy and pulmonary function in children with bronchial asthma.</p><p><strong>Methods: </strong>Clinical data of 120 children with acute asthma attacks (January 2020-December 2023) were retrospectively analyzed. Children were divided into a normal-weight group (16th- < 85th percentile, n=62) and an overweight/obese group (≥ 85th percentile, n=58). Both received standardized treatment. Clinical efficacy, CACT scores, annual attack frequency, emergency visits, inflammatory markers, and pulmonary function were compared.</p><p><strong>Results: </strong>The normal weight group showed significantly higher total effective rate (93.5% vs. 79.3%, P=0.022), better CACT scores post-treatment (23.5 ± 2.8 vs. 19.8 ± 3.2, P < 0.001), and fewer annual attacks (3.2 ± 1.5 vs. 5.6 ± 1.8, P < 0.001) and emergency visits (1.8 ± 1.0 vs. 3.4 ± 1.3, P < 0.001). Both groups improved in pulmonary function and inflammatory factors (all P < 0.05), but the improvement rates in FEV₁ (23.5 ± 7.2% vs. 31.7 ± 8.5%), FEV₁/FVC (13.1 ± 4.8% vs. 17.9 ± 5.6%), PEF (25.7 ± 7.5% vs. 35.7 ± 9.2%), and FEF50% (5.2 ± 4.5% vs. 27.9 ± 7.8%) were significantly lower in the overweight/obese group (all P < 0.05).</p><p><strong>Conclusion: </strong>Overweight and obesity are associated with poorer treatment response, less pulmonary function improvement, and worse disease control in asthmatic children. Weight management should be emphasized in this population to optimize therapeutic outcome.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7107-7117"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liraglutide in combination with zoledronic acid and calcium carbonate and vitamin D3 for diabetic osteoporosis: efficacy and glycometabolism impact.","authors":"Zhen Wu, Jinchan Guo, Qinghe Liu, Jinting Jiang, Bohan Li","doi":"10.62347/KQUI1289","DOIUrl":"10.62347/KQUI1289","url":null,"abstract":"<p><p>This study focuses on people with diabetic osteoporosis (DOP), exploring the efficacy of triple therapy with liraglutide (LIR), zoledronic acid (ZOL) and Calcium Carbonate and Vitamin D3 (CCD3) and the impact of this regimen on glycometabolism (GM). Ninety-nine eligible DOP patients visiting our hospital (January 2023-December 2025) were selected and assigned to a control group (n=46; receiving ZOL + CCD3) and a research group (n=53; receiving LIR + ZOL + CCD3) based on their treatment regimen. Between-group comparisons were made regarding of: efficacy, electrolyte metabolism (calcium [Ca], phosphorus [P]); bone metabolism (bone-specific alkaline phosphatase [BALP], secreted frizzled-related protein 5 [SFRP5], β-C-terminal telopeptide of type 1 collagen [β-CTX]), GM (glycosylated hemoglobin [HbA1c], fasting plasma glucose [FPG], fasting insulin [FINS]), glycemic variability (mean/largest amplitude of glycemic excursion [MAGE/LAGE], coefficient of variation [CV]), hepatorenal function (alanine aminotransferase [ALT], serum creatinine [SCr]), inflammatory cytokines (interleukin [IL]-6, IL-8, tumor necrosis factor-α [TNF-α]) and adverse drug reactions (ADRs; flatulence, nausea, fatigue, abdominal pain and fever). The analysis results showed that compared with controls, the total effective rate of the research group was increased, Ca, BALP and SFRP5 were elevated and the post-medication P, β-CTX, GM indices, glycemic variability parameters and inflammatory markers were decreased (P<0.05). No significant changes in hepatorenal function were observed within (pre- vs. post-treatment) or between groups. The total ADR rate was equivalent across the groups. It is suggested that concomitant administration of LIR, ZOL and CCD3 can significantly improve curative efficacy and ameliorate GM in DOP patients without compromising hepatorenal function.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"18 8","pages":"7297-7305"},"PeriodicalIF":1.8,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}